Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Jeri Matera"'
Autor:
Leon W. M. M. Terstappen, Jonathan W. Uhr, Arjan G. J. Tibbe, Chandra Rao, Mark C. Connelly, Madeline Repollet, M. Craig Miller, Jeri Matera, W. Jeffrey Allard
Supplementary Methods, Figure 1 and Tables 1-2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7309c8118b97214d5bb799139c8cf13f
https://doi.org/10.1158/1078-0432.22440541
https://doi.org/10.1158/1078-0432.22440541
Autor:
Leon W. M. M. Terstappen, Jonathan W. Uhr, Arjan G. J. Tibbe, Chandra Rao, Mark C. Connelly, Madeline Repollet, M. Craig Miller, Jeri Matera, W. Jeffrey Allard
Purpose: The purpose of this study was to determine the accuracy, precision, and linearity of the CellSearch system and evaluate the number of circulating tumor cells (CTCs) per 7.5 mL of blood in healthy subjects, patients with nonmalignant diseases
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c7809b369ed47cd2181297d1825b7bd
https://doi.org/10.1158/1078-0432.c.6517855
https://doi.org/10.1158/1078-0432.c.6517855
Autor:
Mathew J. Ellis, Daniel F. Hayes, Allison Stopeck, Madeline Repollet, Ernest C. Borden, Leon W.M.M. Terstappen, Gerald V. Doyle, Jeri Matera, G. Thomas Budd, Massimo Cristofanilli, M. Craig Miller
Publikováno v:
Clinical Cancer Research. 12:6403-6409
Purpose: The presence of ≥5 circulating tumor cells (CTC) in 7.5 mL blood from patients with measurable metastatic breast cancer before and/or after initiation of therapy is associated with shorter progression-free and overall survival. In this rep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d213d61826de63b0e30cd1b0e1af19f5
https://doi.org/10.1158/1078-0432.ccr-05-1769
https://doi.org/10.1158/1078-0432.ccr-05-1769
Autor:
Gerald V. Doyle, Jeri Matera, Daniel F. Hayes, Massimo Cristofanilli, W. Jeffrey Allard, Leon W.W.M. Terstappen, Matthew J. Ellis, A. Stopeck, G. Thomas Budd, M. Craig Miller
Publikováno v:
Clinical Cancer Research. 12:4218-4224
Purpose: We reported previously that ≥5 circulating tumor cells (CTC) in 7.5 mL blood at baseline and at first follow-up in 177 patients with metastatic breast cancer (MBC) were associated with poor clinical outcome. In this study, additional follo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4956c25027cfcadc90a304a3ca12b52e
https://doi.org/10.1158/1078-0432.ccr-05-2821
https://doi.org/10.1158/1078-0432.ccr-05-2821
Autor:
James M. Reuben, G. Thomas Budd, Matthew J. Ellis, Massimo Cristofanilli, Jeri Matera, Gerald V. Doyle, Alison Stopeck, W. Jeffrey Allard, M. Craig Miller, Leon W.M.M. Terstappen, Daniel F. Hayes
Publikováno v:
New England Journal of Medicine. 351:781-791
We tested the hypothesis that the level of circulating tumor cells can predict survival in metastatic breast cancer.In a prospective, multicenter study, we tested 177 patients with measurable metastatic breast cancer for levels of circulating tumor c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::001b287dbef7acbf847ed227c2971f79
https://doi.org/10.1056/nejmoa040766
https://doi.org/10.1056/nejmoa040766
Autor:
Youn C. Park, Jeri Matera Hynds, James Lamberti, Robert P. Baughman, Mark J. Rumbak, James Taylor, Jeffrey Freitag, Edward Abraham, Stephen O. Heard, Jay S. Steingrub, Howard Levy, Loren D. Nelson, Eugene Fletcher
Publikováno v:
Critical Care Medicine. 27:1478-1485
Objective To evaluate the safety and efficacy of an intravenous liposomal dispersion of prostaglandin E1 as TLC C-53 in the treatment of patients with acute respiratory distress syndrome (ARDS). Design Randomized, prospective, multicenter, double-bli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::41226f1ce64129422a8ad86a9c15c499
https://doi.org/10.1097/00003246-199908000-00013
https://doi.org/10.1097/00003246-199908000-00013
Autor:
Leon W.M.M. Terstappen, G. Thomas Budd, Massimo Cristofanilli, Herbert A. Fritsche, M. Craig Miller, Daniel F. Hayes, James M. Reuben, A. Stopeck, Gabriel N. Hortobagyi, W. Jeffrey Allard, Mathew J. Ellis, Jeri Matera, Gerald V. Doyle
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(7)
Purpose Metastatic breast cancer (MBC) is incurable; its treatment is palliative. We investigated whether the presence of circulating tumor cells (CTCs) predicts treatment efficacy, progression-free survival (PFS), and overall survival (OS) in patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a02c145d8bc143f5a21d84445dca664b
https://pubmed.ncbi.nlm.nih.gov/15735118
https://pubmed.ncbi.nlm.nih.gov/15735118
Autor:
Leon W.M.M. Terstappen, Arjan G.J. Tibbe, Mark Connelly, W. Jeffrey Allard, Jonathan W. Uhr, Chandra Rao, Jeri Matera, M. Craig Miller, Madeline Repollet
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 10(20)
Purpose: The purpose of this study was to determine the accuracy, precision, and linearity of the CellSearch system and evaluate the number of circulating tumor cells (CTCs) per 7.5 mL of blood in healthy subjects, patients with nonmalignant diseases
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fac8f517b652c42fb85d5d27c241a3c9
https://pubmed.ncbi.nlm.nih.gov/26133774
https://pubmed.ncbi.nlm.nih.gov/26133774
Autor:
Laslo Roman, M. Biakhov, Antonio Llombart, Marcel Rozencweig, Nozar Azarnia, Clifford A. Hudis, Alexey Manikhas, José Baselga, Salvatore Forenza, Lokanatha Dasappa, Javier Cortes, Ronald H. Goldfarb, Jeri Matera, Lorena de la Peña, Vladimir Semiglazov
Publikováno v:
Journal of Clinical Oncology. 31:517-517
517 Background: M in combination with T has shown promising activity and cardiac safety in MBC patients (pts). We conducted a randomized Phase III trial of first-line M plus T and P (MTP) versus T plus P (TP) in HER2+ MBC pts. Methods: Pts with HER2+
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4c044523525b8184e69bc24d81c2b23
https://doi.org/10.1200/jco.2013.31.15_suppl.517
https://doi.org/10.1200/jco.2013.31.15_suppl.517
Autor:
Steven J. Cohen, Leon W.M.M. Terstappen, T. M. Fynan, Gerald V. Doyle, Neal J. Meropol, Cornelis J. A. Punt, Jeri Matera, Edith P. Mitchell, Tianyu Li
Publikováno v:
Journal of Clinical Oncology. 24:3531-3531
3531 Background: Lack of validated surrogate endpoints is an impediment to developing new cancer therapy. We hypothesized that CTC and CEC could predict outcome in pts undergoing treatment for mCRC. Methods: Eligible pts for this multicenter study ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3320141a37a8c9b4bf5779d0d2dd64d6
https://doi.org/10.1200/jco.2006.24.18_suppl.3531
https://doi.org/10.1200/jco.2006.24.18_suppl.3531